Next-generation proteasome inhibitors for cancer therapy
Over two decades ago, the proteasome was considered a risky or even untenable therapeutic target. Today proteasome inhibitors are a mainstay in the treatment of multiple myeloma (MM) and have sales in excess of three billion US dollars annually. More importantly, the availability of proteasome inhibitors has greatly improved the survival and quality of life for patients with MM. Despite the remarkable success of proteasome inhibitor therapies to date, the potential for improvement remains and the development and optimal use of proteasome inhibitors as anticancer agents continues to be an active area of research.
Source: Translational Research - Category: Research Authors: Ji Eun Park, Zachary Miller, Yearin Jun, Wooin Lee, Kyung Bo Kim Source Type: research